Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (15789)	2/28/2006 3:54:46 PM
From: Galirayo	Respond to of 23958

[HYC] Looking Good ... stockcharts.com

To: Jibacoa who wrote (15789)	3/1/2006 8:34:01 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[GNTA] Genasense(R) New Drug Application Accepted for Review by FDA Wednesday March 1, 8:00 am ET NDA Proposes Use of Genasense plus Chemotherapy for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia biz.yahoo.com BERKELEY HEIGHTS, N.J., March 1 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Genasense® (oblimersen sodium) Injection. The NDA proposes the use of Genasense plus fludarabine and cyclophosphamide for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The filing was granted an action date by FDA under the Prescription Drug User Fee Act (PDUFA) of October 28, 2006. ADVERTISEMENT "This filing represents the first NDA for a drug that promotes chemotherapy-induced apoptosis in hematologic oncology," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development, and Chief Medical Officer. "We plan to work closely with FDA as we seek approval to commercialize this new treatment option for patients with advanced CLL."